Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer and Merck KGaA win over NICE on Bavencio coverage

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Apr 08, 2022 10:22am

216 Views

Post# 34587646

RE:RE:RE:RE:Pfizer and Merck KGaA win over NICE on Bavencio coverage

Yes it's positive for Oncolytics and breast cancer. A quick search shows there are similarities between Breast and Bladder cancer making a Immunotherapy useful in treating both. --------------------- https://pubmed.ncbi.nlm.nih.gov/29758961/ Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024